We also observed regorafenib dramatically downregulated p-STAT3Tyr705 expression and significant suppression of growth in wild-type SHP-1-expressing CRC cells, but not in D61A and dN1 mutant SHP-1-expressing CRC cells, suggesting that the increased susceptibility to STAT3 dephosphorylation at Tyr705 is due to regorafenib-enhanced SHP-1 activity. This evidence concerns the gene PTPN6 and colorectal carcinoma.